Nadia Khan, MD
Hematology · Chicago, ILNPI 1659531499
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,363 of the $66,241 with a category attached, or 88.1%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.0%. Reporting peaked in 2023 at $21,847 and has fallen 74.5% since, to $5,562 in 2025.
Across 47 payments — averaging $1409.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$14K
- Beigene USA, Inc.$13K
- Johnson & Johnson$11K
- Epizyme, Inc.$6K
- Incyte Corporation$6K
- Janssen Scientific Affairs, LLC$5K
- plus $11K from 9 others
Across 145 payments — averaging $14,993 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$982K
- Eli Lilly$349K
- Genentech, Inc.$187K
- Astrazeneca UK Limited$144K
- Acerta Pharma LLC$137K
- E.r. Squibb & Sons, L.L.C.$116K
- plus $258K from 7 others
What the payments were for
- Consulting fees$58,36388%
- Speaking & faculty fees$5,7389%
- Travel & lodging$1,1312%
- Food & beverage$1,0092%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $13,929 |
| Beigene USA, Inc. | 4 | $13,280 |
| Johnson & Johnson | 5 | $10,892 |
| Epizyme, Inc. | 4 | $5,738 |
| Incyte Corporation | 2 | $5,578 |
| Janssen Scientific Affairs, LLC | 8 | $5,397 |
| Gilead | 8 | $4,917 |
| Genentech, Inc. | 1 | $3,610 |
| Genentech USA, Inc. | 2 | $2,692 |
| AbbVie | 1 | $106 |
| Stemline Therapeutics Inc. | 1 | $26 |
| Amgen | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| CSL Behring | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,241 in reported general payments places this provider in the 80th percentile of 49 hematology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 73 | $1,053,940 |
| VenclextaVenetoclax | 69 | $933,483 |
| BrukinsaZanubrutinib | 29 | $364,972 |
| JaypircaPirtobrutinib | 11 | $247,398 |
| EliquisApixaban | 13 | $7,188 |
| Acyclovir | 62 | $890 |
| Prochlorperazine Maleate | 11 | $144 |
| Allopurinol | 12 | $71 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $13,929 | $1,053,94073 claims |
| AbbVieVenclexta | $106 | $933,48369 claims |
| Beigene USA, Inc.Brukinsa | $13,280 | $364,97229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 49 hematology providers in Illinois.
Other hematology in Chicago
- Jayesh MehtaChicago$183K
- Celalettin UstunChicago$153K
- Kunal DesaiChicago$150K
- John QuigleyChicago$132K
- Parameswa VenugopalChicago$122K
- Seema SinghalChicago$65K
- Olga FrankfurtChicago$49K
- Deborah KatzChicago$38K
- Martin TallmanChicago$28K
- Robert SteinChicago$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.